Japan Cardiac Resynchronization Therapy Market

Japan Cardiac Resynchronization Therapy Market Executive Summary

Japan Cardiac Resynchronization Therapy Market valued at $298 Mn in 2022, projected to reach $458 Mn by 2030 with a 5.5% CAGR.

Cardiac resynchronization therapy (CRT) is a medical procedure involving the utilization of a pacemaker to rectify the heart's rhythm through a minimally invasive surgical procedure. The CRT pacemaker, positioned beneath the skin, harmonizes the timing between the upper and lower heart chambers, ensuring synchronization between the left and right sides of the heart. This therapeutic approach holds particular significance for individuals experiencing heart failure, as it addresses insufficient pumping and fluid accumulation in the lungs and legs resulting from the asynchronous beating of the heart's lower chambers. In instances of severe heart rhythm irregularities, CRT therapy may be complemented by the integration of an implantable cardioverter-defibrillator (ICD). The CRT device connects wires from the pacemaker to both sides of the heart, employing biventricular pacing to guarantee coordinated contractions and optimize overall heart function.

Heart disease and cerebrovascular illness rank as the second and fourth leading causes of death in Japan, respectively. Cardiovascular diseases (CVDs) contribute to over 310,000 deaths annually, with heart disease alone accounting for about 30% of health insurance claims. In 2021, heart-related deaths reached a ten-year high of over 214.7 thousand cases, underscoring the growing incidence of cardiovascular conditions in Japan. Addressing these challenges requires a sustained effort to mitigate the impact of CVDs on public health and healthcare infrastructure.

MicroPort CRM's Alizea pacemakers with Bluetooth technology have received regulatory approval from Japan's PMDA, enhancing remote monitoring capabilities for cardiac patients. Similarly, Medtronic's Micra AV transcatheter pacing system, the world's first leadless pacemaker, has also gained PMDA approval and launched in Japan. These advancements represent a significant leap forward in cardiac care, providing innovative tools for effective patient management and improving the overall quality of care and quality of life for patients in Japan.

Market Dynamics

Market Growth Drivers

Expanding Aging Population: As of 2023, Japan holds the distinction of being the world's most aged country, with over 30% of its population aged 65 and above, a figure anticipated to rise to 40% by 2060. This demographic shift, characterized by a growing elderly population, particularly susceptible to heart-related conditions, highlights an expanded pool of potential candidates for interventions like Cardiac Resynchronization Therapy (CRT).

Increasing Incidence of Heart Failure: The rising rate of heart failure in Japan is a serious health concern, primarily due to an aging population and increased risks like obesity, diabetes, and hypertension. This results in a larger group of patients who could potentially experience benefits from CRT therapy.

Technological Advancements: Continuous improvements in CRT technology are yielding systems that are more durable and smaller, along with new features like data analysis and remote monitoring. These advancements have the potential to enhance patient comfort, treatment efficacy, and the overall delivery of healthcare services.

Market Restraints

Infrastructure and Resource Constraints: In certain areas, the limited healthcare infrastructure and a shortage of skilled medical professionals may impede the widespread adoption of CRT. The lack of specialized facilities and well-trained personnel can restrict access to these advanced therapies.

Limited Awareness and Education: Limited awareness among healthcare professionals and the general public regarding the benefits and applications of CRT has the potential to hinder its acceptance. It might be essential to introduce educational campaigns and training programs aimed at improving awareness and understanding.

High Cost of CRT Devices and Procedures: The expenses linked to CRT devices and the procedures for their implantation can pose a notable obstacle, especially in areas with constrained financial resources. Challenges related to affordability and reimbursement may restrict accessibility for a substantial segment of the population.

Healthcare Policies and Regulatory Landscape

In Japan, the regulatory framework overseeing therapeutic medications is administered by the Pharmaceuticals and Medical Devices Agency (PMDA). The PMDA assesses the safety, effectiveness, and quality of pharmaceuticals, including therapeutic drugs, before granting market approval. Working in conjunction with the PMDA, the Ministry of Health, Labor, and Welfare (MHLW) plays a crucial role in formulating healthcare policies and ensuring that drugs comply with national health standards. Conditional approvals may be issued based on preliminary results, and companies are required to conduct post-marketing assessments to gather additional data on the efficacy and safety of the drugs. The MHLW is responsible for overseeing the national health insurance system, shaping coverage policies, and determining reimbursement guidelines for therapeutic drugs. To foster international collaboration in drug development and distribution, Japanese pharmaceutical firms often engage in global partnerships and licensing agreements.

Competitive Landscape

Key Players

• Abbott
• Biotronik
• Boston Scientific
• Medtronic
• Nihon Kohden
• Oscor
• Siemens Healthineers
• Sorin Group
• MicroPort CRM
• Osram Health